In effort to fast track therapies, IDefine joins consortium
They say that two heads are better than one.
So, imagine the wealth of knowledge in COMBINEDBrain, the Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders. The nonprofit consortium brings together 30 patient advocacy groups to speed the path to clinical treatments for people with severe rare genetic, nonverbal neurodevelopmental disorders by pooling efforts, studies and data.
IDefine is pleased to announce it is COMBINEDBrain’s newest partner organization.
“We know it will take a village to accomplish our goals, so it is really exciting to join this community dedicated to fast-tracking cures and therapies for our rare genetic disorders,” said Geoff Rhyne, CEO of IDefine.
COMBINEDBrain, which represents more than 6,000 families with children with intellectual disabilities, is the brainchild of the mother of a child with a rare genetic disease. It launched in 2019 in Nashville.